These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 33058036

  • 21. Steroid Withdrawal Using Everolimus in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus.
    Nanmoku K, Shinzato T, Kubo T, Shimizu T, Kimura T, Yagisawa T.
    Transplant Proc; 2018 May; 50(4):1050-1055. PubMed ID: 29631750
    [Abstract] [Full Text] [Related]

  • 22. Cytomegalovirus in renal transplant recipients from living donors with and without valganciclovir prophylaxis and with immunosuppression based on anti-thymocyte globulin or basiliximab.
    Andrade-Sierra J, Heredia-Pimentel A, Rojas-Campos E, Ramírez Flores D, Cerrillos-Gutierrez JI, Miranda-Díaz AG, Evangelista-Carrillo LA, Martínez-Martínez P, Jalomo-Martínez B, Gonzalez-Espinoza E, Gómez-Navarro B, Medina-Pérez M, Nieves-Hernández JJ.
    Int J Infect Dis; 2021 Jun; 107():18-24. PubMed ID: 33862205
    [Abstract] [Full Text] [Related]

  • 23. Preventive effect of early introduction of everolimus and reduced-exposure tacrolimus on renal interstitial fibrosis in de novo living-donor renal transplant recipients.
    Ishida H, Ogura G, Uehara S, Takiguchi S, Nakagawa Y, Hamano N, Koizumi M, Wada T, Fukagawa M, Nakamura M.
    Clin Exp Nephrol; 2020 Mar; 24(3):268-276. PubMed ID: 31792639
    [Abstract] [Full Text] [Related]

  • 24. Everolimus vs Mycophenolate Mofetil in Combination With Tacrolimus: A Propensity Score-matched Analysis in Liver Transplantation.
    De Simone P, Carrai P, Coletti L, Ghinolfi D, Petruccelli S, Precisi A, Campani D, Marchetti P, Filipponi F.
    Transplant Proc; 2018 Dec; 50(10):3615-3620. PubMed ID: 30577246
    [Abstract] [Full Text] [Related]

  • 25. Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
    Miranda TA, Felipe CR, Santos RHN, Medina Pestana JO, Tedesco-Silva Junior H.
    Ther Drug Monit; 2020 Dec; 42(6):811-820. PubMed ID: 32657909
    [Abstract] [Full Text] [Related]

  • 26. Clinical Outcomes of Everolimus With Reduced-Dose Tacrolimus vs Mycophenolate Mofetil With Standard-Dose Tacrolimus in De Novo ABO-Incompatible Kidney Transplant Recipients: 1-Year Follow-up.
    Kosoku A, Iwai T, Uchida J.
    Transplant Proc; 2022 Mar; 54(2):293-298. PubMed ID: 35031117
    [Abstract] [Full Text] [Related]

  • 27. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center.
    Ciancio G, Tryphonopoulos P, Gaynor JJ, Guerra G, Sageshima J, Roth D, Chen L, Kupin W, Mattiazzi A, Tueros L, Flores S, Hanson L, Powell RH, Ruiz P, Vianna R, Burke GW.
    Transplant Proc; 2016 Mar; 48(6):2006-10. PubMed ID: 27569936
    [Abstract] [Full Text] [Related]

  • 28. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
    Lo A, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Kisilisik AT, Trofe J, Alloway RR, Gaber LW, Gaber AO.
    Transpl Infect Dis; 2001 Mar; 3(1):8-15. PubMed ID: 11429034
    [Abstract] [Full Text] [Related]

  • 29. Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients.
    Nogueras López F, Abellan Alfocea P, Ortega Suazo EJ, López Garrido MA, Becerra Massare A, Gila Medina AM, Redondo Cerezo E, Espinosa Aguilar MD.
    Transplant Proc; 2020 Mar; 52(2):556-558. PubMed ID: 32035673
    [Abstract] [Full Text] [Related]

  • 30. Outcomes of Everolimus Plus Standard-Dose Tacrolimus Immunosuppression in De Novo Kidney Transplant: A Retrospective, Single-Center Study of 225 Transplants.
    Okabe Y, Noguchi H, Sato Y, Mei T, Kaku K, Ueki K, Tsuchimoto A, Nakamura M.
    Exp Clin Transplant; 2022 Mar; 20(4):362-369. PubMed ID: 35475420
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients.
    Hannun P, Felipe C, Ferreira A, Sandes-Freitas T, Cristelli M, Aguiar W, Franco M, Campos E, Gerbase de Lima M, Tedesco-Silva H, Medina-Pestana J.
    Ther Drug Monit; 2016 Jun; 38(3):293-9. PubMed ID: 26919549
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Cardiovascular Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Calcineurin Inhibitor or Standard Triple Therapy: 24-month Post Hoc Analysis From TRANSFORM Study.
    Sommerer C, Legendre C, Citterio F, Watarai Y, Oberbauer R, Basic-Jukic N, Han J, Gawai A, Bernhardt P, Chadban S.
    Transplantation; 2023 Jul 01; 107(7):1593-1604. PubMed ID: 36959121
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Effective and Safe Reduction of Conventional Immunosuppressants Using Everolimus in Maintenance Kidney Transplant Recipients.
    Nanmoku K, Kurosawa A, Kubo T, Shinzato T, Shimizu T, Kimura T, Yagisawa T.
    Transplant Proc; 2017 Oct 01; 49(8):1724-1728. PubMed ID: 28923615
    [Abstract] [Full Text] [Related]

  • 38. Tailoring tacrolimus therapy in kidney transplantation.
    Jouve T, Noble J, Rostaing L, Malvezzi P.
    Expert Rev Clin Pharmacol; 2018 Jun 01; 11(6):581-588. PubMed ID: 29779413
    [Abstract] [Full Text] [Related]

  • 39. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
    Limaye AP, Budde K, Humar A, Vincenti F, Kuypers DRJ, Carroll RP, Stauffer N, Murata Y, Strizki JM, Teal VL, Gilbert CL, Haber BA.
    JAMA; 2023 Jul 03; 330(1):33-42. PubMed ID: 37279999
    [Abstract] [Full Text] [Related]

  • 40. 5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment.
    Hiramitsu T, Okada M, Futamura K, Yamamoto T, Tsujita M, Goto N, Narumi S, Watarai Y, Takeda A, Iwasaki K, Uchida K, Kobayashi T.
    Int Immunopharmacol; 2016 Oct 03; 39():192-198. PubMed ID: 27491025
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.